"Benzamides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
BENZOIC ACID amides.
| Descriptor ID |
D001549
|
| MeSH Number(s) |
D02.065.277 D02.241.223.100.100 D02.455.426.559.389.127.085
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzamides".
Below are MeSH descriptors whose meaning is more specific than "Benzamides".
This graph shows the total number of publications written about "Benzamides" by people in this website by year, and whether "Benzamides" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2002 | 1 | 5 | 6 |
| 2003 | 0 | 11 | 11 |
| 2004 | 0 | 8 | 8 |
| 2005 | 0 | 5 | 5 |
| 2006 | 0 | 6 | 6 |
| 2007 | 1 | 5 | 6 |
| 2008 | 1 | 7 | 8 |
| 2009 | 1 | 9 | 10 |
| 2010 | 0 | 9 | 9 |
| 2011 | 3 | 8 | 11 |
| 2012 | 4 | 9 | 13 |
| 2013 | 4 | 6 | 10 |
| 2014 | 6 | 4 | 10 |
| 2015 | 2 | 2 | 4 |
| 2016 | 3 | 3 | 6 |
| 2017 | 3 | 7 | 10 |
| 2018 | 1 | 2 | 3 |
| 2019 | 2 | 6 | 8 |
| 2020 | 4 | 5 | 9 |
| 2021 | 4 | 3 | 7 |
| 2022 | 0 | 6 | 6 |
| 2023 | 2 | 1 | 3 |
| 2024 | 3 | 3 | 6 |
| 2025 | 2 | 4 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzamides" by people in Profiles.
-
Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: the AUGMENT-101 study. Blood. 2025 Aug 28; 146(9):1065-1077.
-
EZH2 inhibitor SHR2554 enhances the anti-tumor efficacy of HDAC inhibitor Chidamide through STAT1 in T-cell lymphoma. Cell Death Dis. 2025 Jul 14; 16(1):522.
-
Profound phenotypic deficiencies in mature blood and bone marrow progenitor dendritic cells in chronic lymphocytic leukemia patients. Leukemia. 2025 Aug; 39(8):1915-1927.
-
Azacitidine, Venetoclax, and Revumenib for Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML. J Clin Oncol. 2025 Aug 10; 43(23):2606-2615.
-
Dual Targeting EZH2 and Histone Deacetylases in Human Uterine Sarcoma Cells Under Both 2D and 3D Culture Conditions. J Cell Mol Med. 2025 Jun; 29(11):e70626.
-
Enzalutamide and Prostate-Specific Antigen Levels in Metastatic Prostate Cancer: A Secondary Analysis of the ARCHES Randomized Clinical Trial. JAMA Netw Open. 2025 05 01; 8(5):e258751.
-
Mpox Clinical Presentation, Diagnostic Approaches, and Treatment Strategies: A Review. JAMA. 2024 11 19; 332(19):1652-1662.
-
Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101). J Clin Oncol. 2025 Jan; 43(1):75-84.
-
A Phase I Trial of Enzalutamide Plus Selective Glucocorticoid Receptor Modulator Relacorilant in Patients with Metastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2024 Jun 03; 30(11):2384-2392.
-
Survival by first-line therapy and prognostic group among men with metastatic castration-resistant prostate cancer. Cancer Med. 2024 Jun; 13(12):e7334.